Piramal Pharma Limited has successfully completed its strategic acquisition of Kenalog, a branded commercial injectable product, marking a significant expansion of its pharmaceutical portfolio. The acquisition was finalized on 1st April, 2026, through the company's step-down wholly owned subsidiary, Piramal Critical Care B.V.

Acquisition Details

The transaction involved the acquisition of Kenalog and its associated brands from Bristol-Myers Squibb Company (BMS). This completion follows the company's earlier market intimation dated 28th January, 2026, which had initially disclosed the planned acquisition to regulatory authorities.

Strategic Impact

The successful completion of the Kenalog acquisition represents a strategic enhancement to Piramal Pharma's existing pharmaceutical offerings. The transaction specifically strengthens the company's Complex Hospital Generics portfolio, positioning it for enhanced competitiveness in specialized therapeutic segments.

Market Expansion

With this acquisition, Piramal Pharma reinforces its presence across multiple key international markets. The expanded portfolio will strengthen the company's footprint in:

• United States market
• European markets
• Asia Pacific region

The acquisition aligns with the company's strategy to expand its presence in critical care and hospital-based pharmaceutical products, leveraging the established brand recognition and market positioning of the Kenalog product line.

Regulatory Compliance

The acquisition completion was disclosed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made to both BSE Limited and National Stock Exchange of India Limited, ensuring full regulatory compliance and transparency with stakeholders.

Piramal Pharma Limited has announced that it received an Environment, Social and Governance (ESG) rating of 68.5 from SES ESG Research Pvt. Ltd for the financial year 2024-25. The company disclosed this information to stock exchanges on March 20, 2026, under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

ESG Rating Details

The rating assessment was conducted by SES ESG Research based on publicly available data from the company for FY 2024-25. The pharmaceutical company emphasized that it did not directly engage SES ESG for obtaining this rating.

Voluntary Assessment Process

Piramal Pharma clarified that SES ESG Research voluntarily prepared the ESG report by considering various environmental, social, and governance factors that the company has reported publicly. The rating reflects the company's performance across these sustainability parameters without any direct involvement or commissioning from Piramal Pharma.

Regulatory Compliance and Transparency

The disclosure was made in compliance with SEBI listing regulations, ensuring transparency for stakeholders and investors. The company has also made this information available on its official website at piramalpharma.com, providing easy access to shareholders and other interested parties.

The ESG rating publication by SES ESG Research is available on their official website, offering detailed insights into the methodology and factors considered in the assessment. This voluntary rating provides investors and stakeholders with an independent perspective on the company's sustainability practices and governance standards.